Cytosorbents’ (CTSO) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research report released on Thursday morning,Benzinga reports. D. Boral Capital currently has a $10.00 price objective on the medical research company’s stock.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a research note on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $5.38.

Cytosorbents Stock Down 1.2%

Shares of CTSO opened at $0.59 on Thursday. Cytosorbents has a 52 week low of $0.50 and a 52 week high of $1.39. The company has a quick ratio of 1.71, a current ratio of 2.11 and a debt-to-equity ratio of 1.61. The company has a market capitalization of $37.24 million, a price-to-earnings ratio of -4.56 and a beta of 1.36. The stock’s 50-day moving average price is $0.69 and its 200-day moving average price is $0.75.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Wednesday, March 25th. The medical research company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.04). Cytosorbents had a negative net margin of 22.12% and a negative return on equity of 131.86%. The company had revenue of $9.23 million for the quarter, compared to analysts’ expectations of $9.22 million. On average, sell-side analysts predict that Cytosorbents will post -0.3 EPS for the current year.

Hedge Funds Weigh In On Cytosorbents

Several institutional investors and hedge funds have recently modified their holdings of CTSO. Avenir Corp boosted its position in Cytosorbents by 2.9% during the fourth quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after purchasing an additional 147,261 shares in the last quarter. CM Management LLC increased its position in shares of Cytosorbents by 14.6% in the fourth quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock valued at $944,000 after buying an additional 188,372 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of Cytosorbents in the third quarter valued at approximately $161,000. Citadel Advisors LLC raised its stake in shares of Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after buying an additional 36,790 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in shares of Cytosorbents during the 3rd quarter valued at approximately $105,000. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.